clinical trial · NCT05372419
A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Eli Lilly and Company·phase3·completed·n = 90
Atopic DermatitisLebrikizumab
brief summary
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.
started
Jan 12, 2023
primary completion
May 3, 2024
completion
Feb 17, 2025
last updated
Mar 9, 2026
official title
An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol